COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corporation Fundamental Analysis
COSMOS Pharmaceutical Corporation (3349.T) shows moderate financial fundamentals with a PE ratio of 17.47, profit margin of 2.99%, and ROE of 12.02%. The company generates $1042.6B in annual revenue with moderate year-over-year growth of 4.81%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 41.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 3349.T's fundamental strength across five key dimensions:
Efficiency Score
Weak3349.T struggles to generate sufficient returns from assets.
Valuation Score
Moderate3349.T shows balanced valuation metrics.
Growth Score
Moderate3349.T shows steady but slowing expansion.
Financial Health Score
Moderate3349.T shows balanced financial health with some risks.
Profitability Score
Weak3349.T struggles to sustain strong margins.
Key Financial Metrics
Is 3349.T Expensive or Cheap?
P/E Ratio
3349.T trades at 17.47 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 3349.T's PEG of 28.23 indicates potential overvaluation.
Price to Book
The market values COSMOS Pharmaceutical Corporation at 2.02 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.44 times EBITDA. This is generally considered low.
How Well Does 3349.T Make Money?
Net Profit Margin
For every $100 in sales, COSMOS Pharmaceutical Corporation keeps $2.99 as profit after all expenses.
Operating Margin
Core operations generate 3.91 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.02 in profit for every $100 of shareholder equity.
ROA
COSMOS Pharmaceutical Corporation generates $5.75 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
COSMOS Pharmaceutical Corporation generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
COSMOS Pharmaceutical Corporation generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
3349.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
17.47
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
28.23
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.02
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.52
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.15
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.72
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How 3349.T Stacks Against Its Sector Peers
| Metric | 3349.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 17.47 | 28.25 | Better (Cheaper) |
| ROE | 12.02% | 780.00% | Weak |
| Net Margin | 2.99% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.15 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 0.72 | 4.66 | Weak Liquidity |
| ROA | 5.75% | -14687.00% (disorted) | Weak |
3349.T outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews COSMOS Pharmaceutical Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
47.67%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
44.41%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
88.08%
Industry Style: Defensive, Growth, Innovation
High Growth